Antibody-Drug Conjugates (ADCs) Development

Bioconjugation is an expertise that is essential in the creation of antibody-drug conjugates (ADCs). It facilitates the precise linking of biologically active molecules with potent payloads. At Abzena, we are at the forefront of advanced bioconjugation techniques that enhance the creation of stable and effective ADCs. Abzena’s bioconjugation services ensure that your ADC candidates meet the highest standards of efficacy and safety through:

• Linker Payload Design and Synthesis: We specialize in custom synthesis of novel linker payloads for specific ADC targets, ensuring maximum efficacy and minimized.
• Stability Profiling and Release Kinetics: Our bioconjugation processes ensure optimized release kinetics, maintaining payload stability until the target site is reached.
• Matrix Evaluation Approach: Using a matrix evaluation, we guide the development of bioconjugates, helping to de-risk the process and identify the most effective conjugation strategies.

Download our information sheet titled ‘Streamlining Bioconjugation for Antibody-Drug Conjugate Development’ to learn more.

1. ADC administered to patient via intravenous injection
2. Antibody component specifically recognizes and binds to cancer cell receptor
3. Internalization via receptor-mediated endocytosis
4. ADC in endosome
5. Lysosomal proteases degrade ADC, releasing cytotoxic drug
6. Cytotoxic payload free to interact with internal targets
7. Cell undergoes apoptosis (programmed cell death)

To accelerate lead drug candidate selection, we utilize our expertise in identifying and mapping the appropriate design space for the development of your complex Antibody-Drug Conjugates (ADCs). Through the application of our developability assessments, we identify and de-risk your clinical candidates for development and ensure stage-specific milestones are met.

To optimize the design of your molecule, our expert team applies their experience to design the best ADC matrix strategy for you. Your program will benefit from our extensive knowledge of ADCs and bioconjugation. We have experience in the design and development of fully characterized ADCs with a wide range of conventional and novel linkers, cytotoxins, and other payloads. In addition, we provide a range of both proprietary and non-proprietary PEGylation technologies.

Our experts develop robust conjugation processes maximizing conversion to the target species and purification strategies allowing isolation with high recoveries and purity. Critical process parameters are identified at an early stage to ensure the development of a conjugation process, accelerate your lead candidate, and ensure scale-up of manufacturing.

Our unique ThioBridge® platform is truly next-generation conjugation technology. It overcomes some of the shortcomings of first-generation conjugation technologies, by using site-specific conjugation to antibody interchain disulfide. It offers a more uniform DAR profile and stable attachment compared to maleimide conjugation and allows for PK profiles to be optimized with architectural design flexibility when it comes to the payload and spacer.